nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Cardiorenal risk reduction guidance in diabetes: can we reach consensus?
|
Sattar, Naveed |
|
|
8 |
5 |
p. 357-360 |
artikel |
2 |
Cardiovascular and heart failure outcomes with type 2 diabetes therapies: how important is weight loss?
|
Avogaro, Angelo |
|
|
8 |
5 |
p. 353-355 |
artikel |
3 |
β-cell secretory dysfunction: a key cause of type 2 diabetes
|
Holman, Rury R |
|
|
8 |
5 |
p. 370 |
artikel |
4 |
β-cell secretory dysfunction: a key cause of type 2 diabetes – Authors' reply
|
Weir, Gordon C |
|
|
8 |
5 |
p. 370-371 |
artikel |
5 |
Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Leere, Julius Simoni |
|
|
8 |
5 |
p. 407-417 |
artikel |
6 |
Diabetes in Scotland: a rising tide
|
Colhoun, Helen M |
|
|
8 |
5 |
p. 375-376 |
artikel |
7 |
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
|
Yamada, Yuichiro |
|
|
8 |
5 |
p. 377-391 |
artikel |
8 |
DPP-4 inhibitors and venous thromboembolism: an analysis of the WHO spontaneous reporting database
|
Gouverneur, Amandine |
|
|
8 |
5 |
p. 365-367 |
artikel |
9 |
Francesco Rubino: formerly reluctant bariatric surgeon
|
Mitchell, Fiona |
|
|
8 |
5 |
p. 372 |
artikel |
10 |
Giving NCDs the attention they deserve
|
Morgan, Jules |
|
|
8 |
5 |
p. 373 |
artikel |
11 |
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
|
Ghosh-Swaby, Olivia R |
|
|
8 |
5 |
p. 418-435 |
artikel |
12 |
Insulin access and affordability in the USA: anticipating the first interchangeable insulin product
|
Luo, Jing |
|
|
8 |
5 |
p. 360-362 |
artikel |
13 |
Knowledge gaps and weight stigma shape attitudes toward obesity
|
O'Keeffe, Majella |
|
|
8 |
5 |
p. 363-365 |
artikel |
14 |
Leopard skin
|
Henneicke, Holger |
|
|
8 |
5 |
p. 456 |
artikel |
15 |
Obesity-related stigma—hiding in plain sight
|
The Lancet Diabetes & Endocrinology, |
|
|
8 |
5 |
p. 349 |
artikel |
16 |
Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes
|
Scheen, André J |
|
|
8 |
5 |
p. 350-352 |
artikel |
17 |
Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes
|
Ehrmann, Dominic |
|
|
8 |
5 |
p. 436-446 |
artikel |
18 |
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
|
Yabe, Daisuke |
|
|
8 |
5 |
p. 392-406 |
artikel |
19 |
Skeletal protection in patients with primary hyperparathyroidism
|
Minisola, Salvatore |
|
|
8 |
5 |
p. 352-353 |
artikel |
20 |
Stigma: undermining public health
|
Mitchell, Fiona |
|
|
8 |
5 |
p. 374 |
artikel |
21 |
The importance of language in engagement between health-care professionals and people living with obesity: a joint consensus statement
|
Albury, Charlotte |
|
|
8 |
5 |
p. 447-455 |
artikel |
22 |
The NHS long-term plan: a comparison of the narrative used for cancer and obesity
|
Flint, Stuart W |
|
|
8 |
5 |
p. 355-357 |
artikel |
23 |
Type 1 diabetes—origins and epidemiology
|
Howard, Sarah G |
|
|
8 |
5 |
p. 367-368 |
artikel |
24 |
Type 1 diabetes—origins and epidemiology
|
Virtanen, Suvi M |
|
|
8 |
5 |
p. 368-369 |
artikel |
25 |
Type 1 diabetes—origins and epidemiology – Authors' reply
|
Norris, Jill M |
|
|
8 |
5 |
p. 369-370 |
artikel |